Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 19/20 | 0.70 |
| ▸ | LOX | P28300 | 11/20 | 0.70 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226976 | 0.84 | NOS3 (0.53) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL449200 | 0.82 | LOXL2 (1.00) | LOXL2LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL463199 | 0.81 | LOXL2 (0.96) | LOXL2LOXLOXL3 | |
| SCHEMBL2940362 | 0.81 | RECQL (0.50) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL134512 | 0.81 | LOXL2 (0.46) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL31256818 | 0.81 | LOXL2 (0.46) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL2940184 | 0.81 | LOXL2 (0.46) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL30931700 | 0.79 | LOXL2 (0.62) | LOXL2LOXLOXL3 | |
| SCHEMBL28718096 | 0.79 | LOXL2 (0.49) | LOXL2LOXNOS3NOS1NOS2 | |
| SCHEMBL4934891 | 0.79 | LOXL2 (0.67) | LOXL2LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| US-20250282725-A1 | KCNQ POTENTIATORS | Eii Lilly and Company | 2025-09-11 | — | — | US | disclosed |
| US-12344584-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240076269-A1 | KCNQ POTENTIATORS | Eii Lilly and Company (US) | 2024-03-07 | — | — | US | disclosed |
| US-11840516-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3921030-B1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | LILLY CO ELI (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220073464-A1 | KCNQ POTENTIATORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-11208383-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3921030-A1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | Eli Lilly and Company (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006912-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-12344584-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | LOXL2 684/4885LOX 68/4885LOXL3 281/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | LOXL2 1843/4885LOX 542/4885LOXL3 1984/4885 |
| US-11840516-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20240076269-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | LOXL2 1279/4885LOX 507/4885LOXL3 1854/4885 |
| US-11208383-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20220073464-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.